BIOMX PHGE 深 沪
等待开盘 08-16 09:30:00 美东时间
0.5694
+0.066
+13.18%
华盛通- 最 高0.5695
- 今 开0.5031
- 成交量 88.45万股
- 最 低 0.5011
- 昨 收 0.5031
- 总市值 1490.48万
- 52周最高 1.6196
- 市盈率 静 --
- 换手率 3.38%
- 52周最低 0.34
- 委 比 50.00%
- 总股本 2617.63万
- 历史最高 119.00
- 量 比 0.44
- 振 幅 13.60%
- 历史最低 0.34
- 每 手 1
- 风险率 1.05%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多BiomX GAAP EPS of -$0.19
BiomX press release (NYSE:PHGE): Q2 GAAP EPS of -$0.19. Cash balance and restricted cash as of June 30, 2025, were $15.2 million, compared to $18 million as of December 31, 2024. The decrease was prim...
08-13 19:28
BiomX Q2 EPS $(0.19) Beats $(0.33) Estimate, Cash, Cash Equivalents And Restricted Cash Of $15.2M Are Sufficient To Fund Its Operations Into Q1 Of 2026
Positive Phase 2 results for BX211 demonstrated >40% wound size reduction vs. placebo in diabetic foot osteomyelitis patients; Planning underway for potential registrational studyNature Communications publication of
08-13 18:32
Earnings Scheduled For August 13, 2025
Companies Reporting Before The Bell • Evotec (NASDAQ:EVO) is projected to repor...
08-13 16:32
What to Expect from BiomX's Earnings
BiomX (AMEX:PHGE) is gearing up to announce its quarterly earnings on Wednesday...
08-13 03:01
BiomX to Report Second Quarter 2025 Financial Results and Program Updates on August 13, 2025
Biomx Inc., a clinical-stage company advancing phage therapies targeting pathogenic bacteria, announced it will report its second quarter 2025 financial results and program updates before the U.S. market open on August 13, 2025. A conference call and live webcast will be held at 8:00 AM Eastern Time to discuss the results. Registration is recommended 5 minutes before the call. The webcast will be available on the Company’s website.
08-06 12:30
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers BiomX (AMEX:PHGE) shares moved upwards by 40.1% to $0.61 during Tuesda...
08-06 05:07
BiomX Inc. 13G Filing Shows Morgan Stanley Reports 7.1% Stake In Co As Of June 30, 2025
https://www.sec.gov/Archives/edgar/data/1739174/000089542125000454/xslSCHEDULE_13G_X01/primary_doc.xml
08-06 03:31
BiomX Sets 2025 Annual Meeting Date
BiomX ( ($PHGE) ) has provided an update. BiomX Inc. has announced that its 202...
07-30 22:27
BiomX Announces Successful Initiation of Phase 2b Trial with First Patient Dosed in BX004 Program in Patients with Cystic Fibrosis
BiomX Inc. announced the start of its Phase 2b trial for BX004, a phage therapy targeting antibiotic-resistant lung infections in cystic fibrosis patients caused by *Pseudomonas aeruginosa*. This marks a significant milestone in the company's development program. Previous Phase 1b/2a results showed complete bacterial clearance in 14.3% of patients after 10 days of treatment, including those with chronic infections. The company anticipates FDA fee...
07-14 13:00
BiomX Publishes Promising Phase 1b/2a Trial Results
BiomX ( ($PHGE) ) just unveiled an announcement. On July 8, 2025, BiomX Inc. an...
07-08 21:44
